<p>Long-term plasticity, the long-lasting, activity-dependent change in synaptic efficacy, is a fundamental property of the nervous system. Presynaptic forms of long-term plasticity are widely expressed throughout the brain, having been described in regions such as the cortex, cerebellum, hippocampus, thalamus, amygdala and striatum. Presynaptic long-term potentiation (LTP) is associated with an increase in presynaptic release probability, but further evidence of the cellular basis for the change in release probability is not known. At the molecular level, presynaptic LTP is known to require protein kinase A, the synaptic vesicle protein, Rab3A, and the active zone protein, RIM1alpha. RIM1alpha, a presynaptic scaffold protein, binds to many molecules with known functions at different stages of the neurotransmitter release process and the synaptic vesicle cycle. Understanding which interactions of RIM1alpha mediate presynaptic LTP would shed light on the molecular and cellular mechanisms for presynaptic long-term plasticity.</p><p>Here I developed a novel platform to achieve robust acute genetic</p><p>manipulation of presynaptic proteins at hippocampal mossy fiber synapses, where presynaptic LTP is expressed. With this platform, I perform structure-function analysis of RIM1alpha in presynaptic LTP. I find that RIM1alpha phosphorylation by PKA at serine 413 is not required for mossy fiber LTP, nor does RIM1alpha-Rab3A interation. These findings suggest that RIM1alpha, Rab3A and PKA signaling, instead of functioning synergistically, may represent separate requirements for presynaptic long-term plasticity. I then tested whether Munc13-1, a priming protein, is an effector for RIM1alpha in presynaptic LTP and provide the first evidence for the involvement of Munc13-1 in presynaptic long-term synaptic plasticity. I further demonstrate that the interaction between RIM1alpha and Munc13-1 is required for this plasticity. These results further our understanding of the molecular mechanisms of presynaptic plasticity and suggest that modulation of vesicle priming may provide the cellular substrate for expression of LTP at mossy fiber synapses.</p> / Dissertation

La maladie d’Alzheimer (MA) est la forme la plus commune de démence chez les personnes âgées. La maladie se caractérise par des pertes de fonctions cognitives et plusieurs études ont montré une étroite relation entre la neuroinflammation, les déficits synaptiques et la perte des fonctions cognitives dans la MA. L'importance de la composante neuroinflammatoire a été démontrée essentiellement grâce à des données épidémiologiques rapportant une prévalence diminuée de 40 à 70% chez des patients traités chroniquement par des anti-inflammatoires non stéroïdiens (AINS) pour d'autres pathologies. Les AINS sont des inhibiteurs des enzymes de synthèse des prostaglandines. Les prostaglandines sont des métabolites de l’acide arachidonique. Parmi ces prostaglandines, la PGE2 est connue pour moduler la transmission et les plasticités synaptiques dans l’hippocampe et son expression est fortement augmentée dans la maladie d’Alzheimer. De nombreux travaux rapportent l'existence de déficits synaptiques dans la MA, notamment dans l'hippocampe, siège de la mémoire et de l’apprentissage. Ces travaux se sont focalisés sur les déficits postsynaptiques à la synapse archétypique formée entre les cellules pyramidales CA3 et CA1. A l'inverse, la synapse formée entre les fibres moussues et les cellules pyramidales CA3 (FM-CA3) exprime des plasticités présynaptiques atypiques, à court et à long terme, indépendantes des récepteurs NMDA et il n'existe que très peu d'études concernant ces plasticités dans le contexte de MA. L’objectif de cette étude a été de montrer l’implication de PGE2 dans les déficits synaptiques à la synapse FM-CA3 dans un modèle murin de la MA, la souris double transgénique APPswe/PS1ΔE9 (APP/PS1). Nos résultats montrent que l’application exogène de PGE2 chez des souris sauvages entraîne un déficit de plasticité uniquement sur la potentialisation à long terme (PLT) exprimée présynaptiquement via l’activation spécifique du récepteur EP3. Nous montrons aussi que dans la souris APP/PS1, seule cette PLT présynaptique est impactée à partir de 12 mois. Enfin, ce déficit de la PLT présynaptique pour la souris APP/PS1 est réversé par un inhibiteur spécifique des récepteurs EP3 montrant ainsi un rôle clé pour la signalisation PGE2 - EP3 dans les déficits synaptiques hippocampaux de ce modèle murin de la maladie d’Alzheimer. / Alzheimer’s disease (AD) is the most common form of dementia in elder people characterized by a loss of cognitive function linked to synaptic deficits. There is considerable evidence that neuroinflammation and AD are intimately linked. The key role of neuroinflammation in the course of the disease was figured out by epidemiological studies reporting a reduced prevalence to develop AD for patients chronically treated with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Prostaglandins are lipidic mediators derived from arachidonic acid and their synthesis is inhibited by NSAIDs. Among prostaglandins, PGE2 is known to modulate synaptic transmission and plasticity in the hippocampus and its concentration is higher in brains from AD patients. Numerous studies have reported synaptic deficits in the course of AD, mainly in the hippocampus which is essential for cognitive functions like learning or memory formation. The vast majority of these studies were focused on postsynaptic deficits at the canonical CA3-CA1 synapse. On the opposite, the synapse between mossy fiber and CA3 pyramidal cell (Mf-CA3) that express presynaptic short-term and long-term plasticity, was poorly studied in the context of AD. The aim of my project was to decipher the involvement of PGE2 in synaptic deficits in a mouse model of AD, the APPswe/PS1ΔE9 (APP/PS1). Our results show that acute application of PGE2 on wild type young mice impairs only presynaptic long term potentiation (LTP) at the Mf-CA3 synapse via the specific activation of EP3 receptor. In APP/PS1 mice, we demonstrate that the sole deficit at the Mf-CA3 synapse is an impairment of the presynaptic LTP at 12 months of age. Finally we demonstrate that the impaired presynaptic LTP in APP/PS1 mice can be rescued by the acute application of a specific EP3 receptor antagonist, pointing out the key role of PGE2 - EP3 signaling pathway in synaptic deficits in hippocampus in a mouse model of AD.